MIAMI, May 19, 2020 /CNW/ - Cansortium Inc. TIUM CNTMF ("Cansortium" or the "Company"), a vertically-integrated provider of premium-quality medical cannabis, today announced financial results for its fourth quarter and full year ended December 31, 2019. The Company also provided preliminary first quarter 2020 financial metrics and its initial full year 2020 outlook. The Company's audited consolidated financial statements and accompanying notes for fiscal 2019, along with the Management Discussion and Analysis (MD&A) are available under the Company's profile on SEDAR at www.sedar.com and are also accessible through a link on the Investor Relations section of the Company's website at www.getfluent.com.
Executive Chairman Neal Hochberg commented, "Cansortium took significant strides in the second half of 2019 to improve the Company's balance sheet and establish a platform for profitable growth in our core markets of Florida, Michigan, Pennsylvania and Texas. During 2019, we expanded our dispensary footprint in Florida to 18 locations and we operationalized our key cultivation facility in Tampa, which is the cornerstone of our vertically integrated operations in Florida. Since the beginning of 2020, we have continued to make significant improvements to the business and are pleased to share that Q1 2020 marked the first time in the Company's history that Cansortium generated positive EBITDA, driven by strong revenue growth. We believe that revenue growth and profitability will continue to strengthen through the remainder of 2020."
Selected Fourth Quarter 2019 Financial Highlights Versus Fourth Quarter 2018 Results
- Consolidated revenue increased 52 percent to $9.5 million, compared with revenue of $4.9 million for the fourth quarter of 2018
- Consolidated loss from operations totaled $(5.8) million, compared to loss from operations of $(10.2) million for the same period of 2018
- Consolidated Adjusted EBITDA(2) totaled $0.1 million, compared to Adjusted EBITDA(2) loss of $(10.3) million for the same period of 2018
Selected Full Year 2019 Financial Highlights Versus Full Year 2018 Pro-Forma Results(1)
- Consolidated revenue increased 51 percent to $28.5 million, compared with pro-forma revenue of $18.9 million
- Consolidated loss from operations totaled $(30.9) million, compared with pro-forma loss from operations of $(14.0) million
- Consolidated Adjusted EBITDA(2) loss totaled $(6.9) million, compared to Adjusted pro-forma EBITDA(2) loss of $(16.0) million for the same period of 2018
(1) | Pro-forma measures reflect the consolidation of Knox Servicing, which was accounted for as an equity method investment until August 15, |
(2) | Adjusted EBITDA is a non-IFRS financial measure that does not have any standardized meaning prescribed by IFRS and may not be |
Preliminary First Quarter Financial Metrics
The Company intends to avail itself of the 45-day filing extension provided by the Canadian Securities Administrators as blanket relief, and Ontario Instrument 51-502: Temporary Exemption from Certain Corporate Finance Requirements (the "Order"), for periodic filings normally required to be made by issuers during the period from March 23, 2020 to June 1, 2020. Accordingly, the Company will be postponing the filing of its quarterly financial statements for the three months ended March 31, 2020 and the related management's discussion and analysis beyond the original filing deadline of May 31, 2020. In the interim, it is providing the following select preliminary financial metrics for the period.
- Preliminary, unaudited consolidated revenues for the first quarter ended March 31, 2020 totaled approximately $10.2 million, an 85% increase as compared with revenues of $5.5 million in the first quarter of 2019. During the first quarter of 2020, the Company opened its 19th medical marijuana dispensary in Panama City, FL. It operated 9 dispensaries during the comparable period in 2019. In April, the Company opened its 20th Florida dispensary in East Orlando, FL – it's third in the greater Orlando market.
- Q1 2020 marked the first time the Company was EBITDA positive, achieving preliminary EBITDA of $0.1 million and adjusted EBITDA of $0.9 million, compared with EBITDA loss of $(5.5) million and adjusted EBITDA loss of $(3.3) million in the comparable period of 2019.
Initial Full Year 2020 Outlook
The Company is projecting consolidated revenues for 2020 in the range of $55 million to $60 million and adjusted EBITDA of more than $15 million. The forecast is based on projected revenues of at least $45 million for Cansortium's Florida operations with additional revenue from the Michigan, Pennsylvania and Texas markets.
The Company projects that it will open six additional Florida dispensaries during the remainder of 2020. These locations include Coral Gables, Kendall, South Beach (Miami Beach), Coral Springs, Fort Pierce and Deerfield Beach. In addition, the Company expects to develop two new dispensaries in the south-central region of Pennsylvania during 2020 that will begin operating in early 2021.
Mr. Hochberg noted, "Our preliminary first quarter results and full year 2020 outlook reflect confidence in management's ability to execute the operational and financial restructuring plan (the "Plan") developed by the Company's Board of Directors and its Special Committee." The successful completion of Phase One of the Plan included:
- significant staff rationalization and cost savings
- improvements to the Company's main cultivation facility in Tampa to reach full operational capacity
- sale of non-core operations in Canada and Puerto Rico
- extension of near-term debt maturities and reduction of nearly $10 million of contingent liabilities
- completion of a private equity placement for gross proceeds of approximately U.S. $4.6 million to fund strategic growth opportunities
- establishment of a strategic partnership with Moxie to improve cultivation, branding and product mix.
Mr. Hochberg added, "We are proud of management's accomplishments during the past six months and we are now entering Phase Two of the Plan which will focus on growth and long-term shareholder value creation. We believe that Cansortium's projected profitability will enable the Company to pursue the following targeted initiatives:"
- Expand its Florida dispensary network to 26 by the end of 2020
- Augment its Florida cultivation capacity
- Utilize technology and various marketing initiatives to increase sales and customer loyalty
- Generate revenue in Michigan during 2020
- Grow its Pennsylvania dispensary network to three by 2021
- Continue to promote expansion of the medicinal cannabis market in Texas
Mr. Hochberg concluded, "We are committed to carefully focusing our capital and other resources on the most promising, actionable U.S. medical marijuana markets. In Florida, despite the unprecedented challenges presented by the ongoing global COVID-19 pandemic, we are strengthening the Fluent brand's competitive position by continuing to serve Florida's growing medical marijuana patient population as a designated essential service and we continue to grow revenues while managing expenses to drive profitability. Together with additional opportunities in Michigan, Pennsylvania and Texas, we are positioned to make meaningful progress in 2020 toward enhanced cash flow and profitability."
ABOUT CANSORTIUM INC.
Headquartered in Miami, Florida, and operating under the Fluent™ brand, Cansortium is focused on being the highest quality cannabis company in the State of Florida driven by unrelenting commitment to operational excellence from seed to sale. Cansortium has developed strong proficiencies in each of cultivation, processing, retail, and distribution activities, the result of successfully operating in the highly regulated cannabis industry. In addition to Florida, Cansortium is seeking to create significant shareholder value in the attractive markets of Texas, Michigan and Pennsylvania.
Cansortium Inc.'s common shares and warrants trade on the CSE under the symbol "TIUM.U" and "TIUM.WT.U", respectively, and on the OTCQB Venture Market under the symbol CNTMF. Investors can find current financial disclosure and Real-Time Level 2 quotes for the Company on www.otcmarkets.com.
Forward-Looking Information
All projections related to anticipated future results are forward-looking in nature and are subject to risks and uncertainties that may cause actual results to differ, perhaps materially. Projections are predicated on the Company's ability to continue successfully implementing the strategic growth and cost-saving initiatives identified by the Special Committee of the Board. In addition, projections are based on the Company's ability to secure and effectively deploy its capital resources toward those initiatives.
Certain information in this news release, may constitute forward-looking information. In some cases, but not necessarily in all cases, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "targets", "expects" or "does not expect", "is expected", "an opportunity exists", "is positioned", "estimates", "intends", "assumes", "anticipates" or "does not anticipate" or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might", "will" or "will be taken", "occur" or "be achieved". In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts but instead represent management's expectations, estimates and projections regarding future events. Forward-looking information is necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by the Company as of the date of this news release, are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking information, including but not limited to the factors described in the public documents of the Company available at www.sedar.com. These factors are not intended to represent a complete list of the factors that could affect the Company; however, these factors should be considered carefully. There can be no assurance that such estimates and assumptions will prove to be correct. The forward-looking statements contained in this news release are made as of the date of this news release, and the Company expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.
Financial Tables Follow
Cansortium Inc | ||||
Consolidated Statements of Financial Position | ||||
As of December 31, 2019 and 2018 | ||||
(USD '000) | ||||
Restated | ||||
December 31, | December 31, | |||
2019 | 2018 | |||
Assets | ||||
Current assets | ||||
Cash and cash equivalents | $ | 2,516 | $ | 2,026 |
Accounts receivable | 144 | 62 | ||
Inventory | 6,709 | 2,837 | ||
Biological assets | 3,845 | 2,549 | ||
Note receivable | 3,870 | - | ||
Prepaid expenses and other current assets | 556 | 543 | ||
Total current assets | 17,640 | 8,017 | ||
Assets held for sale | 6,301 | - | ||
Property and equipment, net | 19,128 | 18,573 | ||
Intangible assets, net | 98,566 | 105,657 | ||
Right-of-use assets | 20,190 | - | ||
Investment in associate | 3,424 | - | ||
Goodwill | 1,526 | 7,498 | ||
Other assets | 291 | 721 | ||
Total assets | $ | 167,066 | $ | 140,466 |
Liabilities | ||||
Current liabilities | ||||
Accounts payable | $ | 7,860 | $ | 4,910 |
Accrued liabilities | 5,135 | 3,936 | ||
Income taxes payable | 1,492 | - | ||
Derivative liabilities | 13,198 | 10,810 | ||
Current portion of notes payable | 9,350 | 43,845 | ||
Lease obligations | 1,761 | - | ||
Other current liabilities | - | 1,350 | ||
Total current liabilities | 38,796 | 64,851 | ||
Liabilities held for sale | 3,240 | - | ||
Notes payable, net of current portion | 31,053 | 9,454 | ||
Lease obligations, net of current portion | 21,166 | - | ||
Deferred income taxes | 24,957 | - | ||
Other long-term liabilities | 676 | 450 | ||
Total liabilities | 119,888 | 74,755 | ||
Shareholders' equity | ||||
Share capital | 149,322 | 91,655 | ||
Share-based compensation reserve | 2,977 | - | ||
Equity conversion feature | 7,613 | - | ||
Warrants | 11,773 | 296 | ||
Accumulated deficit | (123,785) | (25,237) | ||
Accumulated other comprehensive loss | (563) | (488) | ||
Total shareholders' equity attributable to Cansortium Inc. shareholders | 47,337 | 66,226 | ||
Non-controlling interests | (159) | (515) | ||
Total shareholders' equity | 47,178 | 65,711 | ||
Total liabilities and shareholders' equity | $ | 167,066 | $ | 140,466 |
Cansortium Inc | ||||
Consolidated Statement of Operations | ||||
For the years ended December 31, 2019 and 2018 | ||||
(USD '000) | ||||
For the years ended December 31, | ||||
Restated | ||||
2019 | 2018 | |||
Revenue, net of discounts | $ | 28,511 | $ | 8,061 |
Cost of goods sold | 10,596 | 6,447 | ||
Gross profit before fair value adjustments | 17,915 | 1,614 | ||
Realized fair value of increments on inventory sold | 9,594 | 1,612 | ||
Unrealized change in fair value of biological assets | (9,735) | (2,866) | ||
Gross profit | 18,056 | 2,868 | ||
Expenses | ||||
General and administrative | 21,720 | 16,094 | ||
Share-based compensation | 7,161 | 963 | ||
Sales and marketing | 12,165 | 4,333 | ||
Depreciation and amortization | 7,869 | 1,729 | ||
Total expenses | 48,915 | 23,119 | ||
Loss from operations | (30,859) | (20,251) | ||
Discontinued operations | 12,415 | - | ||
Other expense (income) | ||||
Interest expense, net | 14,811 | 3,794 | ||
Change in fair market value of derivative | (328) | 4,519 | ||
Loss (gain) on investment in associate | 353 | (2,761) | ||
Gain in fair market value of investment in associate | - | (25,693) | ||
Loss on disposal of assets | 2,909 | - | ||
Other expense | 462 | 944 | ||
Total other expense (income) | 18,207 | (19,197) | ||
Loss before taxes | (61,481) | (1,054) | ||
Income taxes | 4,164 | - | ||
Net loss | (65,645) | (1,054) | ||
Net loss attributable to non-controlling interest | (313) | (727) | ||
Net loss attributable to controlling interest | $ | (65,332) | $ | (327) |
Net loss per share | ||||
Basic | $ | (0.35) | $ | (0.01) |
Diluted | $ | (0.35) | $ | (0.01) |
Cansortium Inc | ||||
Consolidated Statement of Cash Flows | ||||
For the years ended December 31, 2019 and 2018 | ||||
(USD '000) | ||||
Restated | ||||
(Note 22) | ||||
2019 | 2018 | |||
Operating activities | ||||
Net loss | $ | (65,645) | $ | (1,054) |
Adjustments to reconcile net loss to net cash used in operating activities: | ||||
Share-based compensation | 6,652 | 3,690 | ||
Depreciation and amortization | 8,871 | 2,599 | ||
Unrealized gain on changes in fair value of biological assets | (9,735) | (2,866) | ||
Accretion of convertible debentures | 5,578 | 895 | ||
Discontinued operations | 12,415 | - | ||
Change in fair market value of derivative | (328) | 4,519 | ||
Loss (gain) on investment in associate | 353 | (2,761) | ||
Loss of disposal of property and equipament | 2,909 | 570 | ||
Gain in fair market value of investment in associate | - | (25,693) | ||
Interest on lease liabilities | 2,281 | - | ||
Deferred tax expense | 2,671 | - | ||
Changes in operating assets and liabilities: | ||||
Accounts Receivable | (165) | (30) | ||
Inventory | (4,026) | 27 | ||
Biological assets | 8,439 | 1,762 | ||
Prepaid expenses and other current assets | (506) | 148 | ||
Other assets | 403 | (713) | ||
Accounts payable | 3,565 | 1,743 | ||
Accrued liabilities | 2,487 | 3,398 | ||
Income taxes | 1,492 | - | ||
Other current liabilities | (1,261) | - | ||
Other liabilities | 870 | 1,747 | ||
Net cash used in operating activities | (22,680) | (12,019) | ||
Investing activities | ||||
Purchases of property and equipment | (13,844) | (9,529) | ||
Purchase of intangible assets | (319) | (219) | ||
Notes receivable | (3,870) | - | ||
Business acquisitions, net of cash acquired | - | (88) | ||
Net cash used in investing activities | (18,033) | (9,836) | ||
Financing activities | ||||
Proceeds from IPO | 50,836 | - | ||
Proceeds from issuance of shares | - | 22,046 | ||
Proceeds from issuance of notes payable | 37,584 | 1,495 | ||
Proceeds from sale of property and equipment | 204 | - | ||
Distribution to initial investors | - | (600) | ||
Payment of lease obligations | (3,500) | - | ||
Payment of business acquisition contractual obligation | - | (1,150) | ||
Principal repayments of notes payable | (43,840) | (448) | ||
Net cash provided by financing activities | 41,284 | 21,343 | ||
Effect of foreign exchange on cash and cash equivalents | (75) | (495) | ||
Net increase in cash and cash equivalents | 496 | (1,007) | ||
Cash and cash equivalents, beginning of period | 2,026 | 3,033 | ||
Cash and cash equivalents, end of period | $ | 2,522 | $ | 2,026 |
Cash | $ | 2,516 | $ | 2,026 |
Cash included in assets held for sale | 6 | - | ||
Total cash | $ | 2,522 | $ | 2,026 |
Cash paid during the period for interest | $ | 4,144 | $ | 641 |
Non-cash transactions: | ||||
Notes payable issued to acquire additional non-controlling | ||||
interest of subsidiary | $ | - | $ | 50,199 |
Issuance of shares to acquire additional non-controlling | ||||
non-controlling interest of subsidiary | $ | 9,000 | $ | 11,341 |
Issuance of equity for business acquisition | $ | - | $ | 16,874 |
Issuance of shares for investment in Green Standard | $ | 3,777 | $ | - |
Future equity price guarantee | $ | 2,597 | $ | 3,561 |
Conversion of capital contributions to notes payable | $ | - | $ | 1,809 |
Conversion of accrued interest and notes payable to equity | $ | 2,440 | $ | 4,910 |
Cansortium Inc | ||||||
Financial Highlights | ||||||
For the three months ended December 31, 2019 and 2018 | ||||||
(USD '000) | ||||||
Three months ended | ||||||
Financial results | December 31, 2019 | December 31, 2018 | Variance | |||
Revenue | $ | 9,505 | $ | 4,900 | $ | 4,605 |
Gross profit | $ | 9,382 | $ | 1,404 | $ | 7,978 |
Gross margin | 98.7% | 28.6% | 70.1% | |||
Adjusted gross profit (loss)(1) | $ | 5,731 | $ | (436) | $ | 6,167 |
Adjusted gross margin(1) | 60.3% | -8.9% | 69.2% | |||
Selling, general and administrative expenses | $ | 15,177 | $ | 11,558 | $ | 3,619 |
EBITDA(1) | $ | (24,058) | $ | (11,571) | $ | (12,487) |
Adjusted EBITDA(1) | $ | 95 | $ | (10,297) | $ | 10,392 |
Net loss | $ | (32,770) | $ | (14,896) | $ | (17,875) |
Net loss per share (basic) | $ | (0.18) | $ | (0.11) | $ | (0.07) |
Net loss per share (diluted) | $ | (0.18) | $ | (0.11) | $ | (0.07) |
(1) | Adjusted gross profit, adjusted gross margin, EBITDA and Adjusted EBITDA are non-IFRS financial measures that do not have any standardized meaning prescribed by IFRS and may not be comparable to similar measures presented by other companies. Refer to the reconciliation to IFRS and quarterly results of operations sections at the Company's Management Discussion and Analysis document for reconciliation to IFRS. |
Cansortium Inc | |||||||||||
Financial Highlights | |||||||||||
For the years ended December 31, 2019 and 2018 | |||||||||||
(USD '000) | |||||||||||
PRO-FORMA(1) | |||||||||||
Year ended | Year ended | ||||||||||
Financial results | December 31, 2019 | December 31, 2018 | Variance | December 31, 2018 | Variance vs. 12/31/19 | ||||||
Revenue | $ | 28,511 | $ | 8,061 | $ | 20,450 | $ | 18,850 | $ | 9,661 | |
Gross profit | $ | 18,056 | $ | 2,868 | $ | 15,188 | $ | 15,502 | $ | 2,554 | |
Gross margin | 63.3% | 35.6% | 27.8% | 82.2% | -18.9% | ||||||
Adjusted gross profit(2) | $ | 17,915 | $ | 1,614 | $ | 16,301 | $ | 10,321 | $ | 7,594 | |
Adjusted gross margin(2) | 62.8% | 20.0% | 42.8% | 54.8% | 8.1% | ||||||
Selling, general and administrative expenses | $ | 48,915 | $ | 23,119 | $ | 25,796 | $ | 29,543 | $ | 19,372 | |
EBITDA(2) | $ | (35,686) | $ | 4,796 | $ | (40,482) | $ | (16,869) | $ | (18,817) | |
Adjusted EBITDA(2) | $ | (6,936) | $ | (16,099) | $ | 9,163 | $ | (15,998) | $ | 9,062 | |
Net income (loss) | $ | (65,645) | $ | (1,054) | $ | (64,591) | $ | (23,294) | $ | (42,351) | |
Net income (loss) per share (basic) | $ | (0.35) | $ | (0.01) | $ | (0.35) | $ | (0.17) | $ | (0.18) | |
Net income (loss) per share (diluted) | $ | (0.35) | $ | (0.01) | $ | (0.35) | $ | (0.17) | $ | (0.18) | |
(1) | Pro-forma measures reflect the consolidation of Knox Servicing, which was accounted for as an equity method investment until August 15, |
(2) | Adjusted gross profit, adjusted gross margin, EBITDA and Adjusted EBITDA are non-IFRS financial measures that do not have any |
CANSORTIUM INC.
RECONCILIATION OF NON-IFRS FINANCIAL MEASURES
FOR THE THREE AND TWELVE MONTHS ENDED DECEMBER 31, 2019 AND 2018
(USD '000)
EBITDA
EBITDA is a non-IFRS financial measure that does not have any standardized meaning prescribed by IFRS and may not be comparable to similar measures presented by other companies. The Company calculates EBITDA from net income (loss), plus (minus) interest expense (income), plus income taxes, plus depreciation and amortization, as follows:
Three months ended | ||||||
December | December | |||||
31, 2019 | 31, 2018 | Variance | ||||
Net income (loss) | $ | (32,770) | $ | (14,896) | $ | (17,875) |
Interest expense | 5,025 | 2,217 | 2,808 | |||
Income taxes | 2,456 | - | 2,456 | |||
Depreciation and amortization | 1,231 | 1,108 | 123 | |||
EBITDA | $ | (24,058) | $ | (11,571) | $ | (12,487) |
PRO-FORMA(1) | |||||||||||
Year ended | Year ended | ||||||||||
December | December | Variance | December | Variance | |||||||
31, 2019 | 31, 2018 | 31, 2018 | |||||||||
Net income (loss) | $ | (65,645) | $ | (1,054) | $ | (64,591) | $ | (23,294) | $ | (42,351) | |
Interest expense | 14,811 | 3,794 | 11,017 | 3,800 | 11,011 | ||||||
Income taxes | 4,164 | - | 4,164 | - | 4,164 | ||||||
Depreciation and amortization | 10,984 | 2,056 | 8,928 | 2,625 | 8,359 | ||||||
EBITDA | $ | (35,686) | $ | 4,796 | $ | (40,482) | $ | (16,869) | $ | (18,817) | |
(1) | Pro-forma measures reflect the consolidation of Knox Servicing, which was accounted for as an equity method investment until |
CANSORTIUM INC.
RECONCILIATION OF NON-IFRS FINANCIAL MEASURES
FOR THE THREE AND TWELVE MONTHS ENDED DECEMBER 31, 2019 AND 2018
(USD '000)
Adjusted EBITDA
Adjusted EBITDA is a non-IFRS financial measure that does not have any standardized meaning prescribed by IFRS and may not be comparable to similar measures presented by other companies. The Company calculates adjusted EBITDA from EBITDA plus (minus) unrealized loss (gain) on embedded derivatives, plus (minus) certain one-time non-operating expenses, as determined by management. The reconciliation from EBITDA to Adjusted EBITDA is as follows:
Three months ended | ||||||
December 31, 2019 | December 31, 2018 | Variance | ||||
EBITDA | $ | (24,058) | $ | (11,571) | $ | (12,487) |
Change in fair value of biological assets | (3,651) | (1,840) | (1,811) | |||
Change in fair market value of derivative | 5,844 | 1,580 | 4,264 | |||
Share based compensation | 5,416 | 963 | 4,453 | |||
Discontinued operations | 12,415 | - | 12,415 | |||
Other non-recurring expense | 4,129 | 570 | 3,559 | |||
Adjusted EBITDA | $ | 95 | $ | (10,297) | $ | 10,392 |
PRO-FORMA(1) | |||||||||||
Year ended | Year ended | ||||||||||
December | December | Variance | December | Variance | |||||||
31, 2019 | 31, 2018 | 31, 2018 | |||||||||
EBITDA | $ | (35,686) | $ | 4,796 | $ | (40,482) | $ | (16,869) | $ | (18,817) | |
Change in fair value of biological assets | (141) | (1,254) | 1,113 | (5,181) | 5,040 | ||||||
Change in fair market value of derivative | (328) | 4,519 | (4,847) | 4,519 | (4,847) | ||||||
Gain in fair market value of investment in associate | - | (25,693) | 25,693 | - | - | ||||||
Share based compensation | 7,161 | 963 | 6,198 | 963 | 6,198 | ||||||
Discontinued operations | 12,415 | 0 | 12,415 | - | 12,415 | ||||||
Other non-recurring expenses | 9,643 | 570 | 9,073 | 1,533 | 8,110 | ||||||
Adjusted EBITDA | $ | (6,936) | $ | (16,099) | $ | 9,163 | $ | (15,035) | $ | 8,099 | |
(1) | Pro-forma measures reflect the consolidation of Knox Servicing, which was accounted for as an equity method investment until August 15, |
SOURCE Cansortium Inc
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
